• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喹奴普丁/达福普汀对肠球菌属的体外活性比较

Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.

作者信息

Williams J D, Maskell J P, Whiley A C, Sefton A M

机构信息

Department of Medical Microbiology, St Bartholomew's, London, UK.

出版信息

J Antimicrob Chemother. 1997 May;39 Suppl A:41-6. doi: 10.1093/jac/39.suppl_1.41.

DOI:10.1093/jac/39.suppl_1.41
PMID:9511061
Abstract

The in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. was compared with that of amoxycillin, vancomycin, telcoplanin and erythromycin. The susceptibility of 106 vancomycin-susceptible Enterococcus faecalis, 92 vancomycin-susceptible Enterococcus faecium and 14 vancomycin-resistant enterococci (VRE) was tested. Only one strain of vancomycin-susceptible E. faecium was not susceptible to < or = 0.5 mg/L quinupristin/dalfopristin; this strain required 4 mg/L. All strains of E. faecalis were inhibited by < or = 8 mg/L quinupristin/dalfopristin and all VRE strains were inhibited by < or = 2 mg/L. In contrast, teicoplanin and vancomycin showed inhibitory activity against E. faecalis and E. faecium but not against VRE. Amoxycillin was active against E. faecalis but not usually against E. faecium and showed variable activity against VRE; 38% of E. faecalis, 84% of E. faecium and 80% of VRE strains were resistant to erythromycin. The bactericidal activity of quinupristin/dalfopristin against E. faecium exceeded that of the comparator drugs as judged by MIC:MBC ratios and killing curves. The MBC99 of quinupristin/dalfopristin determined by a microdilution broth technique was < or = 1 mg/L for E. faecium. Four of the five strains of vancomycin-susceptible E. faecium and three of the five VRE strains tested with time-kill curves showed a > or = 2 log reduction in viable count after exposure to quinupristin/dalfopristin for 6 h.

摘要

将奎奴普丁/达福普汀对肠球菌属的体外活性与阿莫西林、万古霉素、替考拉宁和红霉素进行了比较。测试了106株对万古霉素敏感的粪肠球菌、92株对万古霉素敏感的屎肠球菌和14株耐万古霉素肠球菌(VRE)的敏感性。仅1株对万古霉素敏感的屎肠球菌对≤0.5mg/L的奎奴普丁/达福普汀不敏感;该菌株需要4mg/L。所有粪肠球菌菌株均被≤8mg/L的奎奴普丁/达福普汀抑制,所有VRE菌株均被≤2mg/L抑制。相比之下,替考拉宁和万古霉素对粪肠球菌和屎肠球菌有抑制活性,但对VRE无抑制活性。阿莫西林对粪肠球菌有活性,但通常对屎肠球菌无活性,对VRE的活性可变;38%的粪肠球菌、84%的屎肠球菌和80%的VRE菌株对红霉素耐药。根据MIC:MBC比值和杀菌曲线判断,奎奴普丁/达福普汀对屎肠球菌的杀菌活性超过了对照药物。通过微量稀释肉汤技术测定,奎奴普丁/达福普汀对屎肠球菌的MBC99≤1mg/L。在用时间杀菌曲线测试的5株对万古霉素敏感的屎肠球菌中,有4株以及5株VRE菌株中的3株在暴露于奎奴普丁/达福普汀6小时后活菌数减少≥2个对数级。

相似文献

1
Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.喹奴普丁/达福普汀对肠球菌属的体外活性比较
J Antimicrob Chemother. 1997 May;39 Suppl A:41-6. doi: 10.1093/jac/39.suppl_1.41.
2
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.单独及联合使用奎奴普丁/达福普汀对肠球菌属耐药菌株和金黄色葡萄球菌的体外杀菌活性
J Antimicrob Chemother. 1997 May;39 Suppl A:33-9. doi: 10.1093/jac/39.suppl_1.33.
3
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
4
Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.奎奴普丁/达福普汀对万古霉素和庆大霉素耐药的粪肠球菌的杀菌和抑菌活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:23-8. doi: 10.1093/jac/39.suppl_1.23.
5
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.对从美国和加拿大200个医疗中心收集的28000多株近期临床分离菌进行了奎奴普丁-达福普汀(RP 59500,Synercid)的抗菌活性测试。
Diagn Microbiol Infect Dis. 1998 Jul;31(3):437-51. doi: 10.1016/s0732-8893(98)80002-3.
6
Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.奎奴普丁-达福普汀与其他抗生素联合对耐万古霉素肠球菌的抗菌活性
Antimicrob Agents Chemother. 2002 May;46(5):1319-24. doi: 10.1128/AAC.46.5.1319-1324.2002.
7
Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.单独使用或与万古霉素联合使用的奎奴普丁/达福普汀对粪肠球菌结构的影响。
Drugs Exp Clin Res. 1998;24(2):73-6.
8
Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.红霉素耐药性、接种物生长阶段及孵育时间对RP 59500(奎奴普丁-达福普汀)针对耐万古霉素屎肠球菌杀菌活性评估的影响
Antimicrob Agents Chemother. 1997 Dec;41(12):2749-53. doi: 10.1128/AAC.41.12.2749.
9
Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.万古霉素与奎奴普丁/达福普汀联合用药对粪肠球菌的协同活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:63-6. doi: 10.1093/jac/39.suppl_1.63.
10
Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.日本东北地区万古霉素及其他抗菌药物对耐甲氧西林金黄色葡萄球菌和粪肠球菌的体外活性比较
Chemotherapy. 1998 Sep-Oct;44(5):318-23. doi: 10.1159/000007129.

引用本文的文献

1
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
2
Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.耐万古霉素肠球菌:感染性心内膜炎的治疗
Curr Infect Dis Rep. 1999 Jun;1(2):148-152. doi: 10.1007/s11908-996-0022-8.
3
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
4
Streptogramins and their potential role in geriatric medicine.链阳菌素及其在老年医学中的潜在作用。
Drugs Aging. 1998 Dec;13(6):443-65. doi: 10.2165/00002512-199813060-00004.
5
Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.奎奴普丁-达福普汀对革兰氏阳性和阴性菌的抗生素后效应及抗生素后亚抑菌浓度效应
Antimicrob Agents Chemother. 1998 Nov;42(11):3028-31. doi: 10.1128/AAC.42.11.3028.
6
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.在具有模拟心内膜赘生物的体外药效学感染模型中,采用间歇性或持续输注的方式,单独或联合强力霉素,用RP 59500(奎奴普丁-达福普汀)治疗耐万古霉素屎肠球菌。
Antimicrob Agents Chemother. 1998 Oct;42(10):2710-7. doi: 10.1128/AAC.42.10.2710.
7
Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.通过时间杀菌曲线和抗生素后效应方法,对不同最低杀菌浓度(MBC)的万古霉素耐药屎肠球菌,进行奎奴普丁-达福普汀活性的药效学分析。
Antimicrob Agents Chemother. 1998 Sep;42(9):2188-92. doi: 10.1128/AAC.42.9.2188.
8
Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.红霉素耐药性、接种物生长阶段及孵育时间对RP 59500(奎奴普丁-达福普汀)针对耐万古霉素屎肠球菌杀菌活性评估的影响
Antimicrob Agents Chemother. 1997 Dec;41(12):2749-53. doi: 10.1128/AAC.41.12.2749.